GCM
RVNC

Graham Capital Management’s Revance Therapeutics, Inc. RVNC Stock Holding History

Graham Capital Management’s Portfolio RVNC Stock Details RVNC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-418,200
Closed -$2.17M – 1522
2024
Q3 		$2.17M Buy
+418,200
New +$2.08M 0.04% 259

Other funds holding RVNC

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Graham Capital Management's RVNC Position: Q3 2024 in Review

Graham Capital Management sold out of Revance Therapeutics, Inc. (RVNC) in Q3 2024, closing a stake of 417,161 shares — an estimated $2.07M sold.

Graham Capital Management first reported a position in RVNC in Q1 2022 and held it in 4 quarters. The position peaked at $1.07M in Q2 2024. 201 funds tracked by Wall St. Rank hold RVNC as of Q3 2024.

  • Graham Capital Management reported no remaining Revance Therapeutics, Inc. position as of Q3 2024 after selling out during the quarter.
  • Graham Capital Management sold 417,161 Revance Therapeutics, Inc. shares in Q3 2024, an estimated $2.07M.
  • Graham Capital Management first reported a position in Revance Therapeutics, Inc. in Q1 2022 and held it in 4 quarters.
  • Graham Capital Management's Revance Therapeutics, Inc. position peaked at $1.07M in Q2 2024.
  • 201 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q3 2024.

Based on Graham Capital Management's 13F filing for Q3 2024, filed 14 Nov 2024.